BioSig to Present Clinical Observations at Venice Arrhythmias 2019
September 30 2019 - 6:52AM
BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology
company developing a proprietary biomedical signal processing
platform designed to address an unmet technology need for the
electrophysiology (EP) marketplace, today announced the PURE
EPTM System will be highlighted in a poster presentation at the
Venice Arrhythmias conference being held on October 3-5, 2019 in
Venice, Italy.
The poster titled, “Use of a Novel Intracardiac Signal
Processing System during Mapping of Complex Cardiac Arrhythmias” is
authored by Amin Al-Ahmad, M.D., Carola Gianni, M.D., Domenico G.
Della Rocca, M.D., J. David Burkhardt, M.D., Rodney P. Horton,
M.D., G. Joseph Gallinghouse, M.D., Patrick M. Hranitzky, M.D.,
Javier E. Sanchez, M.D., Luigi Di Biase, M.D. and Andrea Natale,
M.D. from Texas Cardiac Arrhythmia Institute in Austin, TX.
The clinical data presented in the poster was collected during two
atrial fibrillation cases conducted with PURE EPTM System in
February 2019.
“We greatly appreciate the clinical expertise and ongoing
research collaboration with the entire team of outstanding
physicians and EP lab staff members at Texas Cardiac Arrhythmia
Institute. Their important work with the PURE EPTM platform is
helping us position our technology for a strong commercial launch.
We look forward to sharing more data and clinical observations in
the months to come,” commented Julie M. Stephenson, Senior Director
of Clinical Affairs of BioSig Technologies, Inc.
After conducting first clinical cases at Texas Cardiac
Arrhythmia Institute in February 2019 BioSig successfully carried
out further patient cases using its PURE EPTM System at
Greenville Memorial Hospital in Greenville, SC and Indiana
University School of Medicine. BioSig was recently added to the
Russell 3000 Index and allowed 33 patent claims covering
its PURE EPTM System.
About Venice Arrhythmias
This biennial event has never disappointed for
its ability to always focus on the most important topics for
research, therapies and clinical practice for the treatment of
cardiac arrhythmias. The Program Committee of Venice Arrhythmias
has always caught the most topical problems and collected the
challenges of the times. They combine the most consolidated
strategies on the theoretical and technological innovations, which
over the years have changed, and are constantly changing, the
diagnostic mode, the operating techniques and the approach with the
patient and their disease.VA has become a place of reference, where
many personalities have shared their great progress, where many
young doctors, confirmed and sustained in their ideas, have found
the opportunity to grow professionally and become in turn the
greatest experts.
About BioSig Technologies BioSig Technologies
is a medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com). Led by a
proven management team and a veteran Board of Directors, BioSig
Technologies is preparing to commercialize its PURE EPTM System.
The technology has been developed to address an unmet need in a
large and growing market.
The Company’s first product, PURE EPTM System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory. The system is indicated for use under the supervision
of licensed healthcare practitioners who are responsible for
interpreting the data. This novel cardiac signal acquisition and
display system is engineered to assist electrophysiologists in
clinical decision-making during electrophysiology procedures in
patients with abnormal heart rates and rhythms. BioSig’s ultimate
goal is to deliver technology to improve upon catheter ablation
treatments for the prevalent and potentially deadly arrhythmias,
Atrial Fibrillation and Ventricular Tachycardia. BioSig has
partnered with Minnetronix on technology development and received
FDA 510(k) clearance for the PURE EPTM System in August
2018.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
54 Wilton Road, 2nd floor
Westport, CT 06880
ndrapeau@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2024 to May 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From May 2023 to May 2024